The Impact of Genomic Profiling for Novel Cancer Therapy--Recent Progress in Non-Small Cell Lung Cancer

Related Experiment Video

Updated: Mar 26, 2026

Author Spotlight: Advancements in Molecular Biomarker Testing for Non-Squamous Non-Small Cell Lung Cancer
07:59

Author Spotlight: Advancements in Molecular Biomarker Testing for Non-Squamous Non-Small Cell Lung Cancer

Published on: September 8, 2023

1.8K

Jingwu Xie1, Xiaoli Zhang1

  • 1Department of Pediatrics, Indiana University School of Medicine, Indianapolis, IN 46202, USA; Department of Biochemistry and Molecular Biology, Indiana University School of Medicine, Indianapolis, IN 46202, USA; Department of Pharmacology and Toxicology, Indiana University School of Medicine, Indianapolis, IN 46202, USA; The Simon Cancer Center and The Wells Center for Pediatrics Research, Indiana University School of Medicine, Indianapolis, IN 46202, USA.

Journal of Genetics and Genomics = Yi Chuan Xue Bao
|February 5, 2016
PubMed

Insights

Genomic analysis has revealed targetable gene alterations, enabling personalized cancer therapies like targeted treatments for lung adenocarcinoma. This approach is revolutionizing cancer care and improving patient outcomes.

Area of Science:

  • Oncology
  • Genomics
  • Molecular Biology

Background:

  • The Human Genome Project completion in 2003 spurred advancements in cancer research.
  • Genomic profiling has identified numerous targetable gene alterations in cancer patients.

Purpose of the Study:

  • To review how gene mutation discovery informs new cancer treatment strategies.
  • To highlight non-small cell lung cancer (NSCLC) as a model for targeted therapy development.
  • To discuss the future implications of cancer genome analyses.

Main Methods:

  • Review of scientific literature on cancer genomics and targeted therapies.
  • Analysis of case studies demonstrating the efficacy of targeted treatments.
  • Discussion of emerging trends in cancer genome analysis.

Main Results:

  • Discovery of actionable mutations (e.g., EGFR, BRAF, ALK fusions) has led to novel targeted therapies.
  • Targeted therapy is now a clinical reality for specific cancers like lung adenocarcinomas and melanomas.
  • Non-small cell lung cancer (NSCLC) serves as a prime example of successful targeted treatment implementation.

Conclusions:

  • Gene mutation discovery is pivotal in advancing personalized cancer medicine.
  • Targeted therapies offer improved outcomes for a subset of cancer patients.
  • Continued cancer genome analysis holds significant promise for future therapeutic innovations.
Keywords:
Gene mutationLung cancerTargeted therapy

More Related Videos

Detection of Targetable Alterations in Non-small Cell Lung Cancer using Next-generation Sequencing05:17

Detection of Targetable Alterations in Non-small Cell Lung Cancer using Next-generation Sequencing

Published on: October 10, 2025

513
Profiling Sensitivity to Targeted Therapies in EGFR-Mutant NSCLC Patient-Derived Organoids08:52

Profiling Sensitivity to Targeted Therapies in EGFR-Mutant NSCLC Patient-Derived Organoids

Published on: November 22, 2021

4.7K

Related Concept Videos

Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
6.3K
Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase01:11

Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase

Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...
67
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
9.1K
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

1.7K
Pharmacogenomics: Identification of New Drug Targets01:29

Pharmacogenomics: Identification of New Drug Targets

Advances in genomics have profoundly influenced drug discovery by increasing both the speed and accuracy of pharmaceutical development. Pharmacogenomics, which examines how genetic variation influences drug response, facilitates the identification of novel therapeutic targets and enables patient stratification for personalized treatment. These strategies contribute to improved drug efficacy, minimized adverse effects, and more efficient clinical trial design.Mapping genetic differences...
76